全髋与全膝关节置换术中常规使用氨甲环酸后血栓栓塞事件风险低
该回顾性研究纳入2007—2013年本机构3159例全髋或全膝关节置换术,术前无禁忌者静脉给予氨甲环酸1 g。术后90天内血栓栓塞事件共31例(1.0%),氨甲环酸组与未用药组事件发生率无显著差异(P=0.55)。作者认为常规静脉使用氨甲环酸似乎安全、血栓栓塞事件发生率低,但需大型前瞻性试验确认。
要点
- 3159例手术中2766例(87.6%)术前接受静脉氨甲环酸1 g,393例(12.4%)未接受。
- 术后90天内血栓栓塞事件共31例(1.0%),两组发生率均为1.0%,无显著差异(P=0.55)。
- 氨甲环酸组中较高年龄(OR=1.06,95%CI 1.02-1.11,P=0.005)和现存心血管疾病(OR=4.78,95%CI 1.72-13.28,P=0.003)与血栓栓塞事件风险增加相关。
核心结论
- 研究结果提示,全髋与全膝关节置换术中常规静脉使用氨甲环酸似乎安全,血栓栓塞事件发生率低,但需大型前瞻性试验确认。
研究设计与样本
- 回顾性研究,纳入2007—2013年本机构施行的3159例全髋或全膝关节置换术。
- 术前无禁忌者静脉给予氨甲环酸1 g,比较用药组与未用药组患者特征、合并症及术后90天内血栓栓塞事件。
- 血栓栓塞事件数据来自丹麦国家患者登记处,采用逻辑回归模型评估预测因素。
主要发现
- 3159例手术中2766例(87.6%)接受氨甲环酸(氨甲环酸+组),393例(12.4%)未接受(氨甲环酸-组)。
- 两组平均年龄、性别分布、美国麻醉医师协会评分、麻醉方式、手术时长、诊断及生存状态差异均有统计学意义(P值<0.05)。
- 所研究的合并症在两组间均有显著差异(氨甲环酸+组 vs 氨甲环酸-组;P值≤0.002)。
- 3159例手术中共发生31例(1.0%)血栓栓塞事件,两组无显著差异(氨甲环酸+组:2766例中27例=1.0%,氨甲环酸-组:393例中4例=1.0%,任何事件P值=0.55)。
- 氨甲环酸+组中0.5%发生深静脉血栓、0.3%发生急性心肌梗死、0.2%发生肺栓塞。
关键数值与推荐
- 氨甲环酸+组中,较高年龄与血栓栓塞事件风险增加相关(OR=1.06,95%CI 1.02-1.11,P=0.005)。
- 氨甲环酸+组中,现存心血管疾病与血栓栓塞事件风险增加相关(OR=4.78,95%CI 1.72-13.28,P=0.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出,尽管结果提示常规静脉使用氨甲环酸似乎安全且血栓栓塞事件发生率低,但需大型前瞻性试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The blood-conserving effect of intravenous (IV) tranexamic acid (TXA) is well-documented for total hip arthroplasty (THA) and total knee arthroplasty (TKA). However, the risk of thromboembolic (TE) events after routine use of TXA is unclear and the safety profile is debated. This retrospective study investigates patient characteristics, occurrences, and predictors of TE events after routine administration of IV TXA in THA and TKA. METHODS: Three thousand one hundred fifty-nine THA or TKA procedures performed from 2007-2013 at our institution were included. IV TXA, 1 g, was administered preoperatively if not contraindicated. Relevant patient characteristics and comorbidity information were extracted locally from the database. Data on TE events occurring within 90 days postoperatively came from The Danish National Patient Registry. Patient characteristics, comorbidities, and TE events were compared between TXA groups. A logistic regression model was used to evaluate predictors of TE events. RESULTS: Of 3159 procedures, 2766 (87.6%) received TXA (TXA+ group) preoperatively, whereas 393 (12.4%) did not (TXA- group). Mean age, distributions of gender, American Society of Anesthesiologists score, anesthesia method, duration of surgery, diagnosis, and survival status were all statistically significant different (P values <.05) between TXA groups. The studied comorbidities were all significantly different (TXA+ vs TXA- group; P values ≤.002). We found 31 (1.0%) TE events out of 3159 procedures, with no significant group difference in TE events (TXA+: 27 out of 2766 = 1.0%, TXA-: 4 out of 393 = 1.0%, P value = .55 for any event). For the TXA+ group, 0.5% suffered from deep venous thrombosis, 0.3% from acute myocardial infarction, and 0.2% from a pulmonary embolism. In the TXA+ group, higher age (odds ratio [OR] = 1.06, 95% confidence interval = 1.02-1.11, P = .005) and present cardiovascular disease (OR = 4.78, 95% confidence interval = 1.72-13.28, P = .003) were associated with an increased risk of TE events. CONCLUSION: The findings suggest that routine use of IV TXA for TKA and THA as safe with low occurrence of TE events, although a large prospective trial should confirm this.
引用
- Madsen RV, Nielsen CS, Kallemose T, et al. Low Risk of Thromboembolic Events After Routine Administration of Tranexamic Acid in Hip and Knee Arthroplasty. J Arthroplasty. 2016. PMID: 27843042. doi:10.1016/j.arth.2016.10.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。